'GSK has reached a licensing agreement with mRNA vaccine developer CureVac worth up to €1.4bn to develop its vaccines for flu, Covid-19 and avian flu.
The UK drugmaker has an existing collaboration with the German vaccine maker but it will pay €400mn to CureVac to take full control of developing vaccines under the agreement.'
https://www.ft.com/content/9974696e-ab2c-497b-853a-ee81f949e356